User profiles for Philippe Gui

Philippe Gui

University of California San Francisco
Verified email at ucsf.edu
Cited by 840

[HTML][HTML] Evolution of metastasis: new tools and insights

P Gui, TG Bivona - Trends in Cancer, 2022 - cell.com
Metastasis is an evolutionary process occurring across multiple organs and timescales. Due
to its continuous and dynamic nature, this multifaceted process has been challenging to …

[PDF][PDF] Therapy-induced evolution of human lung cancer revealed by single-cell RNA sequencing

…, AY Elizabeth, EL Schenk, W Tan, A Zee, M Tan, P Gui… - Cell, 2020 - cell.com
Lung cancer, the leading cause of cancer mortality, exhibits heterogeneity that enables
adaptability, limits therapeutic success, and remains incompletely understood. Single-cell RNA …

[HTML][HTML] The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance

DR Caswell, P Gui, MK Mayekar, EK Law, O Pich… - Nature Genetics, 2024 - nature.com
In this study, the impact of the apolipoprotein B mRNA-editing catalytic subunit-like (APOBEC)
enzyme APOBEC3B (A3B) on epidermal growth factor receptor (EGFR)-driven lung …

[PDF][PDF] Immune cell Toll-like receptor 4 mediates the development of obesity-and endotoxemia-associated adipose tissue fibrosis

…, C Lefort, L Mir, K Louche, V Bourlier, B Roussel, P Gui… - Cell reports, 2014 - cell.com
Adipose tissue fibrosis development blocks adipocyte hypertrophy and favors ectopic lipid
accumulation. Here, we show that adipose tissue fibrosis is associated with obesity and …

Co-occurring alterations in the RAS–MAPK pathway limit response to MET inhibitor treatment in MET exon 14 skipping mutation-positive lung cancer

JK Rotow, P Gui, W Wu, VM Raymond, RB Lanman… - Clinical Cancer …, 2020 - AACR
Purpose: Although patients with advanced-stage non–small cell lung cancers (NSCLC)
harboring MET exon 14 skipping mutations (METex14) often benefit from MET tyrosine kinase …

Rho/ROCK pathway inhibition by the CDK inhibitor p27kip1 participates in the onset of macrophage 3D-mesenchymal migration

P Gui, A Labrousse, E Van Goethem… - Journal of cell …, 2014 - journals.biologists.com
Infiltration of macrophages into tissue can promote tumour development. Depending on the
extracellular matrix architecture, macrophages can adopt two migration modes: amoeboid …

The protease-dependent mesenchymal migration of tumor-associated macrophages as a target in cancer immunotherapy

P Gui, M Ben-Neji, E Belozertseva, F Dalenc… - Cancer immunology …, 2018 - AACR
Macrophage recruitment is essential for tissue homeostasis but detrimental in most cancers.
Tumor-associated macrophages (TAMs) play a key role in cancer progression. Controlling …

Targeted cancer therapy induces APOBEC fueling the evolution of drug resistance

…, PP Argyris, WL Brown, J Yu, C Gomez, P Gui… - Cancer Research, 2022 - AACR
Introduction: Increasing our understanding of drivers of mutagenesis in lung cancer is
critical in our efforts to prevent tumor reoccurrence and resistance. Results: Using the multi-region …

[PDF][PDF] Synthetic essentiality of metabolic regulator PDHK1 in PTEN-deficient cells and cancers

N Chatterjee, E Pazarentzos, MK Mayekar, P Gui… - Cell reports, 2019 - cell.com
Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is a tumor suppressor
and bi-functional lipid and protein phosphatase. We report that the metabolic regulator …

[PDF][PDF] Stepwise evolution of therapy resistance in AML

P Gui, TG Bivona - Cancer Cell, 2021 - cell.com
Relapse of AML patients to FLT3i treatment is the result of a long-term and stepwise process
leading to resistance, whereby residual cancer cells initially survive and subsequently …